Oslo Myeloma Center is the largest center for clinical myeloma research in the Nordics.
In 2020, 93 patients were enrolled in 11 clinical studies, in young and elderly, in newly diagnosed and in patients with one of multiple relapses, in phase, 1,2 and 3 studies.
Number of patients included in the different phases:
Phase 1 - 15 patients
Phase 2 - 43 patients
Phase 3 - 45 patients
The biggest accomplishment during 2019 was to set up the first CAR-T-cell trial for myeloma in the Nordics. In 2020, we enrolled 5 patients to the trial.
We collaborate with basal and translational research groups, especially with the KG Jebsen center for B cell malignancies at our hospital, with projects in drug-sensitivity screening, pathophysiology and immune therapy. In addition, we have a myeloma registry with both prospective and retrospective data.